{"id":49085,"date":"2022-10-03T15:02:05","date_gmt":"2022-10-03T13:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/"},"modified":"2022-10-03T15:02:05","modified_gmt":"2022-10-03T13:02:05","slug":"zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/","title":{"rendered":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange"},"content":{"rendered":"
\n

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2<\/sub>) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc<\/a>, the nation\u2019s largest member-driven health care performance improvement company, will hold the Exchange on October 17 in Dallas.\n<\/p>\n

<\/a><\/p>\n

\nThe annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient\u2019s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.\n<\/p>\n

\nZOLL\u2019s TherOx SSO2<\/sub> Therapy is the first FDA-approved, catheter-based therapy to safely and effectively reduce infarct size (damage to heart muscle) in randomized control trials.1<\/sup> SSO2<\/sub> is used immediately after stenting is performed for left anterior descending (LAD) ST-segment elevation (STEMI) heart attacks \u2014 the most severe type \u2014 and within six hours of symptom onset. SSO2<\/sub> delivers high levels of dissolved oxygen directly to the heart to recover damaged tissue. Data have shown that SSO2<\/sub> is associated with lower rates of heart failure and death within one year.2<\/sup>\n<\/p>\n

\n\u201cSSO2<\/sub> Therapy represents the first major milestone in STEMI care in almost 20 years,\u201d said Christopher Barnabas, President of ZOLL Circulation. \u201cWe feel honored to have been included in this important event and look forward to showcasing SSO2<\/sub> Therapy as the next step in improving care and outcomes for STEMI patients.\u201d\n<\/p>\n

\n\u201cThe Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products. This signals health care providers of a product\u2019s unique qualities,\u201d said Kelly Flaharty, senior director of contract services, Vizient. \u201cWith only a select number of suppliers invited to demonstrate their products, it\u2019s an honor to be invited.\u201d\n<\/p>\n

\nThe annual Innovative Technology Exchange is part of Vizient\u2019s Innovative Technology Program<\/a> that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.\n<\/p>\n

\nAbout ZOLL<\/b>\n<\/p>\n

\nZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com<\/a>.\n<\/p>\n\n\n
\n

\nCopyright \u00a9 2022 ZOLL Medical Corporation. All rights reserved. TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation and\/or its subsidiaries in the United States and\/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n___________________________<\/p>\n\n\n\n
1<\/sup> Stone GW, et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009.<\/a><\/td>\n<\/tr>\n
\n

\n2<\/sup> Chen, et al. Catheter Cardiovasc Interv. 2020;1\u20137.<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact:
\n
Matt Hogan
\n
ZOLL
\n
978-805-6561
\n
media@zoll.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation\u2019s largest member-driven health care performance improvement company, will hold the Exchange on October 17 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49085","6":"format-standard","7":"category-industry"},"yoast_head":"\nZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation\u2019s largest member-driven health care performance improvement company, will hold the Exchange on October 17 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T13:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange\",\"datePublished\":\"2022-10-03T13:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/\"},\"wordCount\":536,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005061\\\/en\\\/1587447\\\/21\\\/ZOLL_AKtag-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/\",\"name\":\"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005061\\\/en\\\/1587447\\\/21\\\/ZOLL_AKtag-01.jpg\",\"datePublished\":\"2022-10-03T13:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005061\\\/en\\\/1587447\\\/21\\\/ZOLL_AKtag-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005061\\\/en\\\/1587447\\\/21\\\/ZOLL_AKtag-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/","og_locale":"en_US","og_type":"article","og_title":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend","og_description":"CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation\u2019s largest member-driven health care performance improvement company, will hold the Exchange on October 17 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-03T13:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange","datePublished":"2022-10-03T13:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/"},"wordCount":536,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/","url":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/","name":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg","datePublished":"2022-10-03T13:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221003005061\/en\/1587447\/21\/ZOLL_AKtag-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/zoll-selected-to-exhibit-therox-sso2-therapy-at-vizient-innovative-technology-exchange\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49085"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49085\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}